Table 2.
Clinical and laboratory characteristics of immunophenotypic T-ALL subcategories among pediatric and adult age groups.
| Parameters | Pediatric patients | Adult patients | |||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| T-ALL subtype | P | T-ALL subtype | P | ||||||||||||
| Con-T-ALL (N=34) |
ETP-ALL (N=7) |
Near-ETP-ALL (N=6) |
ETP-ALL vs. Near- ETP-ALL |
ETP-ALL vs. Con-T-ALL |
Near- ETP-ALL vs. Con-T- T-ALL |
Con-T-ALL (N=15) |
ETP-ALL (N=10) |
Near-ETP-ALL (N=9) |
ETP-ALL vs. Near- ETP-ALL |
ETP-ALL vs. Con- T-ALL |
Near- ETP-ALL vs. Con-T-ALL |
||||
| Median age (range) in years | 12 (1–18) | 16 (13–17) | 13 (5–18) |
0.295 | 0.056 | 0.343 | 25 (20–50) |
34 (19–39) |
29 (20–52) |
0.842 | 0.367 | 0.290 | |||
| Sex (male:female) | 3.8:1 | 6:1 | 5:1 | 0.906 | 0.307 | 0.825 | 6.5:1 | 2.3:1 | 2:1 | 0.876 | 0.702 | 0.243 | |||
| Median (range) Hb in g/L | 91 (30–141) | 97 (30–131) |
83 (41–129) |
0.181 | 0.465 | 0.517 | 89 (63–142) |
80 (61–128) |
88 (69–133) |
0.356 | 0.338 | 1.000 | |||
| Median (range) WBC, ×109/L | 110 (1.9–850) | 90.4 (3.2–267) |
244 (3–590) |
0.366 | 0.198 | 0.810 | 88 (1.1–349) |
55 (1–480) |
68 (3.6–131) |
0.017 | 0.036 | 0.682 | |||
| Median (range) platelet, ×109/L | 83 (22–366) | 125 (30–245) |
149 (32–380) |
0.731 | 0.175 | 0.240 | 52 (20–119) |
125 (30–290) |
100 (20–218) |
0.720 | 0.016 | 0.138 | |||
| Median (range) BM blast, % | 87 (23–97) | 86 (22–98) |
95 (89–99) |
0.149 | 0.845 | 0.029 | 87 (64–96) |
85 (38–95) |
76 (50–97) |
0.863 | 0.770 | 0.446 | |||
| Median (range) PB blast, % | 84 (2–96) | 86 (2–98) |
98 (2–99) |
0.268 | 0.883 | 0.074 | 61 (3–97) |
36 (5–94) |
76 (5–91) |
0.161 | 0.073 | 0.770 | |||
| Hyperleukocytosis | 53% | 29% | 67% | 0.089 | 0.240 | 0.533 | 27% | 10% | 44% | 0.089 | 0.307 | 0.371 | |||
| Hepatomegaly | 45% | 40% | 67% | 0.109 | 0.829 | 0.478 | 36% | 20% | 56% | 0.109 | 0.404 | 0.349 | |||
| Splenomegaly | 61.3% | 40% | 67& | 0.463 | 0.370 | 0.855 | 43% | 50% | 67% | 0.463 | 0.729 | 0.265 | |||
| Lymphadenopathy | 75% | 100% | 100% | 0.906 | 0.207 | 0.207 | 70% | 80% | 78% | 0.906 | 0.560 | 0.658 | |||
| Mediastinal mass | 40% | 20% | 17% | 0.153 | 0.402 | 0.286 | 29% | 40% | 11% | 0.153 | 0.558 | 0.322 | |||
| CNS involvement | 4% | 0% | 0% | NA | 0.638 | 0.638 | 8% | 0% | 0% | NA | 0.452 | 0.620 | |||
| Induction death | 7% | 0% | 0% | 0.098 | 0.508 | 0.508 | 0% | 14% | 60% | 0.098 | 0.162 | 0.002 | |||
| Induction failure | 0% | 0% | 0% | NA | NA | NA | 0% | 17% | 75% | 0.065 | 0.001 | 0.001 | |||
| D8BNC | 30% | 50% | 50% | 0.105 | 0.343 | 0.422 | 40% | 57% | 0% | 0.105 | 0.486 | 0.074 | |||
| EOI-MRD positive | 15% (N=27) |
83% (N=6) |
60% (N=5) |
0.346 | 0.001 | 0.025 | 38.5% (N=13) |
67% (N=6) |
100% (N=2) |
0.346 | 0.252 | 0.104 | |||
| Relapse | 11% (N=27) |
17% (N=6) |
17% (N=6) |
1.000 | 0.706 | 0.706 | 31% (N=13) |
17% (N=6) |
100% (N=2) |
0.035 | 0.278 | 0.278 | |||
| OS at 24 months | 79% (N=29) |
67% (N=6) |
100% (N=6) |
0.564 | 0.820 | 0.297 | 48% (N=13) |
51% (N=7) |
0% (N=5) |
0.025 | 0.588 | 0.001 | |||
| RFS at 24 months | 87% (N=27) |
83% (N=6) |
75% (N=6) |
0.937 | 0.805 | 0.720 | 64% (N=13) |
75% (N=6) |
0% (N=2) |
0.012 | 0.705 | 0.014 | |||
| EFS at 24 months | 81% (N=29) |
80% (N=6) |
75% (N=6) |
0.937 | 0.878 | 0.943 | 45% (N=13) |
54% (N=7) |
0% (N=5) |
0.019 | 0.767 | <0.001 | |||
Abbreviations: BM, bone marrow; CNS, the central nervous system; D8BNC, day 8 blast not cleared; EFS, event-free survival; EOI-MRD, end-of-induction-measurable residual disease; Hb, hemoglobin; N, number of patients analyzed; NA, not applicable; OS, overall survival; PB, peripheral blood; RFS, relapse-free survival; WBC, white blood cells.